Chordia Therapeutics Cash Flow Statement

Financials in millions JPY. Fiscal year is September - August.

Millions JPY. Fiscal year is Sep - Aug.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023
Net Income	-1,786	-1,827	223.34
Depreciation & Amortization	2.7	4.09	6.04
Asset Writedown & Restructuring Costs	13.78	-	-
Other Operating Activities	128.24	-224.68	229.54
Change in Other Net Operating Assets	-195.77	110.46	84.81
Operating Cash Flow	-1,837	-1,937	543.73
Capital Expenditures	-5.33	-0.54	-0.35
Sale (Purchase) of Intangibles	-	-	-0.38
Other Investing Activities	-	-10.42	1.07
Investing Cash Flow	-5.33	-10.96	0.35
Issuance of Common Stock	61.58	1,479	-
Financing Cash Flow	61.58	1,479	-
Miscellaneous Cash Flow Adjustments	-0	-0	0
Net Cash Flow	-1,781	-469.41	544.08
Free Cash Flow	-1,842	-1,938	543.38
Free Cash Flow Margin	-	-	21.73%
Free Cash Flow Per Share	-26.85	-32.99	9.63
Cash Income Tax Paid	2.42	2.42	2.42
Levered Free Cash Flow	-1,192	-1,243	-
Unlevered Free Cash Flow	-1,192	-1,243	-
Change in Working Capital	-195.77	110.46	84.81

Updated Nov 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.